Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/577,815external-prioritypatent/US4005063A/en
Application filed by Abbott LaboratoriesfiledCriticalAbbott Laboratories
Publication of BG60340B2publicationCriticalpatent/BG60340B2/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Нонапептидът намира приложение за третиране на топлокръвни животни. По аналогия на известните методи е получен синтетичен нонапептид с подобрена биологична активност, превъзхождаща тази на естествения фоликулстимулиращ лутеинизиращ хормон, който освобождава хормона (gn-rн). Новият пептид предизвиква овулация при топлокръвните животни в орална доза от 5 до 10 нг/кг. 1 претенцияNonapeptide is used to treat warm-blooded animals. By analogy with known methods, a synthetic nonapeptide with improved biological activity superior to that of the natural follicle-stimulating luteinizing hormone-releasing hormone (gn-rn) was obtained. The new peptide induces ovulation in warm-blooded animals at an oral dose of 5 to 10 ng/kg. 1 claim
BG096331A1975-05-151992-05-13(des-gly)10-gnrh nonapeptide analogue in position 6 with avulation-provoking activity
BG60340B2
(en)
Improvements introduced in the preparation of pharmaceutical compositions in the form of unit dose (Machine-translation by Google Translate, not legally binding)
Hormonal therapy in cancer of the breast. XIII. The effect of 9 alpha-fluoro-17 alpha-methyl-delta 4-androsten3-one-11 beta-17 beta-diol (fluoxymetherone) therapy on clinical course and hormonal excretion
Investigations on the carcinogenic burden by air pollution in man. VI. Experimental investigations to determine a dose-response relationship and to estimate a threshold dose of benzo (a) pyrene in the skin of two different mouse strains